Hosted by Matt Aldrich & Dana Prescott
Downloads
More from: Biologic Wars: Rheumatology Debate Series
Chasing Absolute Zero In Rheumatoid Arthritis
Treat-to-target transformed RA outcomes - not through new drugs but through rigorous measurement and escalation discipline. Sarah Mitchell and James Carter cover the evidence base, the disease activity tools, the window of opportunity in early RA, and when tapering biologics in sustained remission is safe.
Stopping Spinal Fusion Or Protecting The Gut?
PsA is not RA with skin, and axSpA is not RA in the spine. The biologic hierarchy shifts significantly across the spondyloarthropathy spectrum - IL-17 and IL-23 inhibitors dominate, anti-TNF has uveitis caveats, and IBD comorbidity changes everything. Sarah Mitchell and James Carter explain how EULAR 2026 data shapes the choices.
Why Cheaper Humira Alternatives Face Resistance
Adalimumab biosimilars cut NHS spend by over 50% while treating more patients. NOR-SWITCH and subsequent trials consistently show switching from reference biologic to biosimilar is safe. Sarah Mitchell and James Carter explain the regulatory science, the nocebo effect, and how the biosimilar dividend is being reinvested into newer therapies.
- JAK inhibitors offer comparable or superior efficacy to anti-TNF in RA with oral convenience
- ORAL Surveillance: tofacitinib showed significantly higher MACE and malignancies vs anti-TNF in high-CV-risk patients - but population was specifically selected, limiting generalisability
- Boxed warning applies class-wide; guidelines recommend biologics first in high CV, malignancy, or thrombosis risk patients
- Risk-stratified prescribing: younger patients without risk factors remain candidates for JAKi after csDMARD failure
POD-2026-017 - 06/26
Matt Aldrich is a medical science communicator based in Boston. With a background in biomedical research and health journalism, he specialises in translating complex clinical trial data into accessible conversations for healthcare professionals.
Cite This Article
Team TLSFE. The oral surveillance jak inhibitor controversy. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/rheumatology/arthritis-rheumatoid/insights/the-oral-surveillance-jak-inhibitor-controversy.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
[1] Ytterberg SR et al. ORAL Surveillance. N Engl J Med. 2022;386:316-326
[2] Dougados M et al. MONARCH. Ann Rheum Dis. 2017;76:1348-1356
[3] Smolen JS et al. EULAR RA Management Recommendations. Ann Rheum Dis. 2023
[4] Fraenkel L et al. ACR RA Treatment Guidelines. Arthritis Rheumatol. 2021
